Liraglutide Peptide: Weight Research Profile

Curious about Liraglutide’s weight-reduction potential? This handbook covers all the bases for researchers interested in evaluating into chronic weight control compounds. Liraglutide is being explored and researched more and more in studies related to persistent obesity as it has been hypothesized to lower weight and improve metabolic function in many different animal model types.

Our professional team has summarized the existing research on Liraglutide and weight reduction, including the peptide’s possible properties, profile, and mechanism of action. Keep reading for an overview of information available for researchers on Liraglutide and weight.

Liraglutide Peptide: What is it?

Researchers have explored the peptide Liraglutide in different avenues, many of which include studies in the context of type 2 diabetes (T2D) and persistent obesity. The hormone glucagon-like peptide-1 (GLP-1) is synthesized from a naturally occurring substance in the organism in response to dietary consumption. Research indicates that the incretin hormone GLP-1 may stimulate pancreatic insulin secretion, inhibit glucagon release, and decrease glucose production by the liver, all of which may contribute to regulating blood sugar levels.

Liraglutide’s mechanism of action is similar to that of GLP-1. In addition to binding to GLP-1 receptors throughout the organism, it is believed to be 97% identical to the hormone. Stimulating pancreatic receptors may potentially reduce blood sugar levels and improve glycemic control. Additionally, it has been theorized to aid in reducing postprandial glucose levels, suppressing hunger, and promoting sateity in the organism by slowing gastric emptying after a meal.

Liraglutide Peptide and Weight

Several experimental studies have suggested that the peptide may be efficacious in animal models of obesity. Below, read top findings on Liraglutide’s weight loss potential, with detailed information on the possible ways researchers have evaluated Liraglutide’s potential to induce weight loss.

Investigations purport that Liraglutide may activate GLP-1 receptors in several parts of the organism, including the brain, intestines, and fat cells, to promote weight reduction. For instance, Liraglutide has been speculated to potentially suppress hunger as it may bind to and activate GLP-1 receptors in the brain, particularly in areas critical for appetite regulation.

It has been hypothesized to control hunger and appetite by binding GLP-1 receptors on neurons in the hypothalamic arcuate nucleus. These neurons are considered to express the POMC/CART transcript, which is controlled by amphetamines.

In addition to possibly activating POMC/CART neurons directly, Liraglutide is reported to indirectly decrease two orexigenic peptides, NPY and AgRP. This is believed to result in less hunger and more sensations of fullness.

According to the research, Liraglutide seems to also mitigate the decline in leptin resulting from weight reduction. White adipose tissue secretes leptin, another name for the satiety hormone. When the organism loses weight, fat percentage drops, which means leptin levels and their impact on the sensation of fullness are reduced. Findings imply that by interacting with the GLP-1 receptors in adipose tissue, Liraglutide may potentially counteract the decrease in leptin levels after weight reduction.

According to the researchers, another hormone that may promote satiety in the organism, peptide YY (PYY), is linked to increased levels in the Liraglutide peptide. This hormone may decrease hunger by sending messages to the brain when it is full.

Most PYY is endogenously generated in the gut, so it stands to reason that Liraglutide may activate the GLP-1 receptors to cause these effects. Research suggests that Liraglutide may support weight regulation in the long run by potentially raising PYY levels.

Researchers speculate that in the first hour after a meal, Liraglutide appeared to have slowed stomach emptying by 23% compared to a placebo. Since Liraglutide did not appear to increase energy expenditure, the weight loss may have been caused by an appetite-suppressing potential, which may be induced by delayed postprandial stomach emptying.

The researchers did hypothesize that Liraglutide did not appear to significantly impact stomach emptying after three hours of eating. So, whether the delayed stomach emptying that occurs within one to three hours after a meal may significantly enhance the peptide’s possible weight loss properties is still up for debate.

The possible appetite-suppressing properties of Liraglutide may potentially induce substantial weight reduction, as suggested by systematic evaluations of the relevant study literature. It has been hypothesized that 73% of research models appeared to have dropped 5% of weight or more, and 37% seemed to have lost 10% or more.

It is worth mentioning that a systematic review conducted by Konwar et al. in 2022 suggested that Liraglutide may have the potential to cause substantial weight reduction. The analysis included fourteen randomized controlled trials (RCTs). On average, research models exposed to Liraglutide for 20-56 weeks were speculated to lose more weight than placebo groups, as suggested by the meta-analysis.

According to another meta-analysis and systematic review published in 2022, Liraglutide’s weight reduction potential may possibly influence visceral, organ, and subcutaneous fat.

A significant risk factor for chronic illnesses, including type 2 diabetes, heart disease, and certain forms of cancer, excessive visceral fat is often associated with adipose obesity.

For more educational peptide articles and the highest-quality research compounds for research studies, visit biotechpeptides.com.

References

[i] Lin, C. H., Shao, L., Zhang, Y. M., Tu, Y. J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020). An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert opinion on pharmacotherapy, 21(3), 275–285. https://doi.org/10.1080/14656566.2019.1695779

[ii] Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holstw, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010

[iii] Jin, T., & Weng, J. (2016). Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. American journal of physiology. Endocrinology and metabolism, 311(3), E620–E627. https://doi.org/10.1152/ajpendo.00069.2016

[iv] Bode B. (2011). Liraglutide: a review of the first once[1]daily GLP-1 receptor agonist. The American journal of managed care, 17(2 Suppl), S59–S70.

[v] Halawi, H., Khemani, D., Eckert, D., O’Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., Zinsmeister, A. R., & Camilleri, M. (2017). Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The lancet. Gastroenterology & hepatology, 2(12), 890–899. https://doi.org/10.1016/S2468-1253(17)30285-6

[vi] Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015). Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert review of cardiovascular therapy, 13(7), 753–767. https://doi.org/10.1586/14779072.2015.1054810

[vii] Honigberg, M. C., Chang, L. S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020). Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA cardiology, 5(10), 1182– 1190. https://doi.org/10.1001/jamacardio.2020.1966

[viii] Nuffer, W. A., & Trujillo, J. M. (2015). Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy, 35(10), 926–934. https://doi.org/10.1002/phar.1639